These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18458136)

  • 1. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
    Ruan SY; Chu CC; Hsueh PR
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2919-22. PubMed ID: 18458136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
    Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
    Dagi HT; Findik D; Senkeles C; Arslan U
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing epidemiology of candidaemia in Australia.
    Chapman B; Slavin M; Marriott D; Halliday C; Kidd S; Arthur I; Bak N; Heath CH; Kennedy K; Morrissey CO; Sorrell TC; van Hal S; Keighley C; Goeman E; Underwood N; Hajkowicz K; Hofmeyr A; Leung M; Macesic N; Botes J; Blyth C; Cooley L; George CR; Kalukottege P; Kesson A; McMullan B; Baird R; Robson J; Korman TM; Pendle S; Weeks K; Liu E; Cheong E; Chen S;
    J Antimicrob Chemother; 2017 Apr; 72(4):1103-1108. PubMed ID: 28364558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
    Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
    Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN
    J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.
    Kiraz N; Dag I; Yamac M; Kiremitci A; Kasifoglu N; Oz Y
    Antimicrob Agents Chemother; 2010 May; 54(5):2244-7. PubMed ID: 20194697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM; Elizondo M; Ayala J
    J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
    Nagappan V; Boikov D; Vazquez JA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):522-5. PubMed ID: 19841143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies.
    Gil-Alonso S; Jauregizar N; Cantón E; Eraso E; Quindós G
    Antimicrob Agents Chemother; 2015; 59(6):3615-8. PubMed ID: 25801575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
    Chen TC; Chen YH; Chen YC; Lu PL
    Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.
    Chaturvedi V; Ramani R; Andes D; Diekema DJ; Pfaller MA; Ghannoum MA; Knapp C; Lockhart SR; Ostrosky-Zeichner L; Walsh TJ; Marchillo K; Messer S; Welshenbaugh AR; Bastulli C; Iqbal N; Paetznick VL; Rodriguez J; Sein T
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1543-8. PubMed ID: 21282457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
    Burn AK; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; McCarthy DI; Rinaldi MG; Redding SW
    J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
    Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
    J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
    J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibility of Candida isolates at one institution.
    Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J
    Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.
    Sellami A; Sellami H; Néji S; Makni F; Abbes S; Cheikhrouhou F; Chelly H; Bouaziz M; Hammami B; Ben Jemaa M; Khaled S; Ayadi A
    Mycopathologia; 2011 Jun; 171(6):417-22. PubMed ID: 21170738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.